ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1477

Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials

Vibeke Strand1, Rita Ganguly2, Nan Li3, Prasheen Agarwal3, Shihong Sheng3, Kaiyin Fei3, Kelly McQuarrie3 and Sharon Popik3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2GlaxoSmithKline, Collegeville, PA, 3Janssen Research & Development, LLC, Spring House, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologics, Clinical Response, patient-reported outcome measures, rheumatoid arthritis (RA) and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases.  Effects of sirukumab on RA symptoms and disease activity and health-related physical and emotional well-being were evaluated in 2 phase 3 randomized controlled trials (RCTs) in RA pts with inadequate responses to conventional DMARDs (SIRROUND-D) or TNF inhibitors (TNFi; SIRROUND-T).  Across both RCTs, significant improvements were observed in all 8 SF-36 domains with both evaluated sirukumab doses (50 mg q4w and 100 mg q2w) versus placebo (PBO; P<0.001).

Methods: In both RCTs, eligible pts were randomized (1:1:1) to treatment with SC sirukumab 50 mg q4w, sirukumab 100 mg q2w, or PBO.  Durations of PBO treatment were 52 and 24 wks, respectively, in SIRROUND-D and SIRROUND-T.  Efficacy of sirukumab was evaluated using traditional RA endpoints.  This analysis included SDAI and CDAI scores and the following patient-reported outcomes (PROs): pt global assessment of disease activity, pain (0-10 VAS), HAQ-DI, FACIT-Fatigue, and SF-36 health survey.  In this post-hoc analysis, correlations between changes from baseline (BL; at Wks 16 [primary endpoint] or 24) in disease activity, symptoms, and SF-36 domain scores were evaluated.  Last observation carried forward was used for imputing missing data.

 

Results: For changes from BL to Wk 16 in SIRROUND-T, correlation coefficients (r) were low to moderate between all 8 SF-36 domains and SDAI (r ranging from −0.535 to −0.208) and CDAI (−0.526 to −0.209; Table).  Low to moderate correlations were also observed between changes from BL to Wk 16 in 7 of 8 SF-36 domains and pt global assessment scores (r ranging from −0.461 to −0.267) in SIRROUND-T, and a high correlation was observed for the remaining domain, bodily pain (−0.665 to −0.619).  Moderate correlations were observed between changes from BL to Wk 16 in the SF-36 bodily pain, physical function, social function, and role-physical domains and changes in HAQ-DI (r ranging from −0.560 to −0.310).  Moderate to high correlations were observed for changes from BL to Wk 16 in 7 of 8 SF-36 domains and FACIT-Fatigue scores (r ranging from 0.392 to 0.627; Table).  As anticipated, changes from BL to Wk 16 in VAS pain and SF-36 bodily pain domain were highly correlated (r ranging from −0.672 to −0.661; Table).  Correlations were generally higher with sirukumab than placebo.  Similar correlations were observed in changes from BL to Wk 16 in SIRROUND-D.  These correlations were maintained at Week 24 in both RCTs.

 

Conclusion: Results of these analyses highlight the importance of PROs, including SF-36 and FACIT-Fatigue, as independent measures of treatment success.  Although some SF-36 domains are moderately correlated with clinical responses, these findings indicate that SF-36 captures aspects of patient well-being not covered by standard measures of RA symptoms and disease activity.


Disclosure: V. Strand, AbbVie, Amgen, AstraZeneca, Biogen Idec, Boehringer Ingelheim, Celltrion, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sanofi, and UCB, 5; R. Ganguly, GlaxoSmithKline, 1,GlaxoSmithKline, 3; N. Li, Johnson & Johnson, 3,Johnson & Johnson, 1; P. Agarwal, Johnson & Johnson, 1,Johnson & Johnson, 3; S. Sheng, Johnson & Johnson, 1,Johnson & Johnson, 3; K. Fei, Johnson & Johnson, 1,Johnson & Johnson, 3; K. McQuarrie, Johnson & Johnson, 1,Johnson & Johnson, 3; S. Popik, Johnson & Johnson, 1,Johnson & Johnson, 3.

To cite this abstract in AMA style:

Strand V, Ganguly R, Li N, Agarwal P, Sheng S, Fei K, McQuarrie K, Popik S. Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/patient-reported-outcomes-as-independent-measures-of-treatment-success-with-sirukumab-an-anti-il6-cytokine-monoclonal-antibody-in-patients-with-active-rheumatoid-arthritis-post-hoc-analysis-of-2-pl/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-as-independent-measures-of-treatment-success-with-sirukumab-an-anti-il6-cytokine-monoclonal-antibody-in-patients-with-active-rheumatoid-arthritis-post-hoc-analysis-of-2-pl/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology